| Last Verified: | February/28/2015 |
| First Submitted: | June/29/2010 |
| Estimated Enrollment Submitted: | July/5/2010 |
| First Posted: | July/6/2010 |
| Last Update Submitted: | March/15/2015 |
| Last Update Posted: | March/16/2015 |
| Actual Study Start Date: | July/31/2010 |
| Estimated Primary Completion Date: | February/28/2013 |
| Estimated Study Completion Date: | February/28/2013 |
| Study Type: | Interventional |
| Allocation: | Randomized |
| Primary Purpose: | Treatment |
| Masking: | Double (Participant, Outcomes Assessor) |
| Arm | Intervention/treatment |
|---|---|
| Placebo Comparator: Control group A (control) will receive a bolus of normal saline (20 mL per side) followed by a continuous infusion of normal saline (7 ml/h per side) via both TAP catheters.The infusions will be started after the bolus doses and continued postoperatively for 48 hours. | Procedure: Control A bolus of normal saline (20 mL per side) followed by a continuous infusion of normal saline (7 ml/h per side. The infusions will be started after the bolus doses and continued postoperatively for 48 hours. |
| Experimental: TAP group B (TAP) will receive a bolus of lidocaine 1% with epinephrine 1:200 000 (20 mL per side) followed by a continuous infusion of ropivacaine 0.2% (7 mL/h per side) via TAP catheters. The infusions will be started after the bolus doses and continued postoperatively for 48 hours. | Procedure: TAP A bolus of lidocaine 1% with epinephrine 1:200 000 (20 mL per side) followed by a continuous infusion of ropivacaine 0.2% (7 mL/h per side). The infusions will be started after the bolus doses and continued postoperatively for 48 hours. |
| Ages Eligible for Study: | 18 Years to 18 Years |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
| Criteria: | Inclusion Criteria: - Age: 18 years and over - ASA class 1, 2 - Elective open radical prostatectomy Exclusion Criteria: - Any history or signs of cardiac, hepatic and renal failure. Patients with raised serum LFTs and serum creatinine outside normal range - Any chronic use of opioid analgesic - Morbid obesity (BMI>40) - History of allergic reactions to any of the study medications and the medications used for the trial - Pregnancy - Previous abdominal surgery |